Immunai to Advance Inflammatory Bowel Disease Target with AstraZeneca

Immunai, an AI biotech company specializing in mapping the human immune system, has joined forces with AstraZeneca for the development of a target for inflammatory bowel disease (IBD), which was identified through Immunai’s Immunodynamics Engine (IDE).

Under the terms of the agreement, AstraZeneca will gain exclusive rights to develop and commercialize therapeutics directed at the target. Immunai will receive an upfront payment and is eligible to receive up to $85 million in total consideration.

The target was discovered using Immunai’s platform, which integrates clinically annotated single-cell multi-omics datasets with machine learning to model immune function and dysfunction across disease states. The platform is designed to enable rapid, scalable identification of immune-modulating targets across a range of indications, including oncology, autoimmunity, and inflammatory disorders.

“Target discovery has always been a challenging process, especially in complex immune diseases like IBD,” said Noam Solomon, PhD, co-founder and CEO of Immunai. “This agreement marks a turning point. We’re showing that by modeling the immune system with high-resolution single-cell data and artificial intelligence, we are able to not just find new targets, but also understand why they matter. We’re proud to expand our collaboration with AstraZeneca, supporting them to discover and develop new therapies.”

This milestone builds on a multi-year collaboration between the two companies which began in 2022. In 2024, AstraZeneca committed $18 million to leverage Immunai’s proprietary platform and machine learning capabilities to inform certain oncology clinical trials. The collaboration is focused on clinical decision-making, including dose selection, elucidating mechanisms of action, patient responder vs. non-responder analysis, and biomarker identification , using Immunai’s IDE.